NEW YORK (GenomeWeb News) – Shares of Sequenom rose around 20 percent for the second straight day after the firm reported yesterday that a blinded study showed that its molecular test for Down syndrome correctly identified 100 percent of all Down syndrome samples without any false-positive outcomes.
That announcement pushed Sequenom’s shares up 22 percent yesterday.
Today, in heavy trading on the Nasdaq — around 10 times its average daily volume — shares of Sequenom climbed another 19.5 percent to close at $11.15.